

Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc.

Novo Nordisk Inc. has recalculated its 340B ceiling prices for the period Q3 2020 for the products listed below due to revisions made to their Medicaid pricing data. Novo Nordisk Inc. has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about Novo Nordisk Inc.'s recalculation affecting certain 340B Covered Entities for the impacted product(s).

Novo Nordisk Inc. has determined the credit amount owed to each affected covered entity. Novo Nordisk Inc. will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds for each affected Covered Entity. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or a check will be issued to Covered Entities whose wholesaler account cannot be identified.

NDC	Product Description
00169-2550-13	TRESIBA FLEXTOUCH U200
00169-2800-15	SAXENDA
00169-4132-12	OZEMPIC 0.25MG/0.5MG
00169-4136-02	OZEMPIC 1MG 2X1.5ML

If a Covered Entity believes they are due a refund and are not contacted by Apexus by June 23, 2023, you may contact Novo Nordisk Inc., at NNIBIDNOTIFICATION@novonordisk.com.